Cancer, it causes and treatments, remains one of the largest areas of bilogical and clinical research globally. Treatments for cancer are very diverse and span many different mechanisms of action as well as molecule classes. For example, there are very efficious small moleucle kinase inhibitors as well as larger moleucule monoclonal antibody inhibitors of growth factor receptors. To address these needs, Aragen Bioscience offers a diverse range of oncology disease models and services to provide the most appropriate study design for the specific project needs. These models range from human xenograft tumor models to the more complex sub-renal capsule, patient derived xenograft (PDX), and Syngeneic tumor models.
Human Cell Line Xenograft Models
Indeed, there are hundreds of cell lines, various mouse strains, multiple implantation techniques that can be utilized in a xenograft model. Aragen has experience with xenograft models of lymphoma, leukemia, lung cancer, breast cancer, colon cancer, melanoma, and other indications. These can be run in nude or SCID mice as well as in the nude rat. Depending on the needs of the study and the mechanism of action of the molecules, these tumors can be implanted subcutaneously, orthotopically, within the sub-renal capsule or, in some cases, run as a metastatic model. Importantly, as we have experience in both large and small molecule therapeutics, our team is well trained on the various dosing methods and regimes required for these studies.
Syngeneic Tumor Models
If the mechanism of action requires in intact immune system, the immuno-compromised setting required for a xenograft model will not be appropriate for efficacy assessment. In such cases, syngeneic models, where the strain of the derived tumor cell line and the host animal are the same, may be more appropriate. Aragen has performed may various syngeneic model including models of breast, colon, liver, and lung cancers as well as melanoma and lymphoma models.
Patient Derived Xenograft Tumor Models
Recently, efforts have been made to create oncology models that more closely represent the biology and therapeutic responses observed in human patients. To that end, models have been generated in which tumor tissue derived directly from human patients is implanted and grown in immuno-compromised mice. This type of model is referred to as a “Patient Derived Xenograft” or a PDX model. Aragen has evaluated a number of various compounds in PDX models and has gained significant experience in this novel model class.